# Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

> **NCT03204734** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 132 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** endocrine therapy

## Key facts

- **NCT ID:** NCT03204734
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03204734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03204734, "Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03204734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*